A lot of eyes now on AVXL since CTAD. Once we get past Friday options hope to see greener pastures next week. Also some serious posters who had previously said trial was illegitimate are now taking the 52 week data very seriously. Next look for Biogen update with A-273. Further phase 2/3 developments.